as of 11 December 2019 2 /NTA (Net Tangible Assets) is equal to total assets less intangible assets, total liabilities and non-controlling interests 3/ Profits during the last 12 months (only a portion

Total shareholders’ equity 22,342.4 30,004.5 (7,662.1) Remark (1) Comprised of discount on changes in shareholding in subsidiaries and non-controlling interests of the subsidiaries As of 31 March 2020

expenses (reversal) 0.0 0.0 0.0 - - Profit before income tax expenses 139.0 183.0 138.7 -0.2% -24.2% Tax expenses (reversal) 7.5 42.4 20.6 +174.4% -51.5% Profit (loss) attributable to non- controlling

shareholders and directors of Modern Pharma Company Limited are not Executive Committee and shareholders including those with controlling power in the company. Therefore, it is not considered a connected

debts 7,515,428 801,233 Interests without controlling power 573,262 11 Net tangible asset (NTA) 2,765,616 660,210 Net profit 620,824 208,793 Proportion 100% Enclosure 1 5 information in the consolidated

(expense) 203 214 271 34% 27% 271 - Finance cost (1,217) (1,171) (1,201) -1.3% 2.6% (1,564) (363) Income tax (1,523) (1,303) (1,397) -8.3% 7.2% (1,335) 62 Non-controlling interest (1.0) (0.8) (1) -23% -7.4

120 196 44% 63% 731 986 35% Finance cost 1,358 1,414 1,366 0.6% -3.4% 5,917 5,626 -4.9% Income tax 1,128 1,399 1,522 35% 8.8% 5,089 5,970 17% Non-controlling interest -1 -0.6 -1 12% 25% -3 -2 -20% Net

-50 % Finance cost 1,366 1,294 1,294 -5.3 % —% 5,626 5,231 -7.0 % Income tax 1,522 1,410 1,747 15 % 24 % 5,970 6,168 3.3 % Non-controlling interest -0.7 -0.7 -0.7 —% 5.1 % -2 -3 13 % Net profit for the

-controlling interest -1 -1 0 -127% -119% -3 -3 7.9% Net profit for the period 7,363 8,146 7,003 -4.9% -14% 26,011 29,086 12% EBITDA (Bt mn) 4Q22 3Q23 4Q23 %YoY %QoQ FY22 FY23 %YoY Operating Profit 9,807 10,805

20% Non-controlling interest -1.3 -0.4 -0.5 64% -14 % -2.0 -0.9 57% Net profit for the period 7,180 8,451 8,577 19% 1.5% 13,937 17,028 22% EBITDA 23,256 27,769 27,621 19% -0.5% 45,817 55,389 21% EBITDA